gasworld interviews Jerry Shelton, Cryoport’s CEO following the company’s expansion in The Netherlands with its new Global Logistics Centre in Amsterdam.
Cryoport, a US-based provider of cold chain logistics solutions serving multiple markets including biopharmaceutical, IVF and surrogacy and animal health organisations worldwide, has opened its new Global Logistics Centre in Amsterdam.
The new facility will help Cryoport as it prepares for the substantial increase in the number of trials within the regenerative medicine sector, as well as the ramping of commercial products it currently supports. gasworld spoke to Jerry Shelton, CEO of Cryoport to find out what this means for the market and Cryoport’s development.
“As of the end of 2018, there were 1,028 trials in the regenerative therapy market, up from 631 at the end of 2015. We feel that the number of trials and the advancement of current trials will continue in 2019,” said Shelton.
“Our new Cryoport Global Logistics Centre in Amsterdam adds to our ability to better serve them. Additionally, our new centre located in Amsterdam will support the first European commercially approved cellular therapies from Novartis (Kymriah) and Gilead (Yescarta).”
gasworld asked Shelton why the company chose Amsterdam as the location of its new state of the art facility.
“Amsterdam is a world-leading hub for the life sciences industry,” said Shelton.
“It supports the life sciences industry in many ways including the Amsterdam Science Park, an incubator for the development of health care businesses and special support of areas around the Schiphol Amsterdam Airport and the Port of Amsterdam, which offers strategic logistics hub locations,” said Shelton.
The new centre adds to Cryoport’s already global network, supporting the distribution of biopharmaceutical products requiring exacting temperature and condition controls.
There are currently 241 ongoing trials in the regenerative medicine centre taking place in Europe and Israel, making the new centre key for Cryoport’s company development.
“Our Amsterdam Global Logistics Centre will allow us to deliver same day or next day to most of Europe. This gives our clients more flexibility and enables us to better meet their demands,” said Shelton.
Cryoport now has multiple facilities that are located globally. The company has four Global Logistics Centres and one embedded centre.
“They are located in Irvine, California; Livingston, New Jersey; Amsterdam, The Netherlands and Singapore. Our embedded logistics centre is located in Charles City, Iowa and supports a Zoetis vaccine manufacturing facility,” Shelton told gasworld.
Shelton shared his thoughts on Cryoport’s future plans for expansion and how the company will continue to meet the rapidly developing regenerative therapy market.
“We will definitely increase the number of Global Logistics Centre in the future. The pace of the build out will be driven by client demand. Other locations will probably be in the US, China, Europe and possibly Japan,” said Shelton.
“With the development of cellular therapies, we think demand will continue to grow globally. We also plan to introduce some new cryogenic packaging technologies to the market this year.”
“We have focused heavily on the regenerative medicine space over the past 3-4 years. Our goal now is to leverage our strong industry leading position into broader offerings, more complex supply chain support, which would potentially include bio-storage, kitting and fulfilment services,” Shelton concluded.